Update on nifurtimox for treatment of Chagas disease
Copyright 2021 Clarivate Analytics..
Chagas disease is a vector-borne neglected tropical disease caused by Trypanosoma cruzi. It is a systemic and chronic parasitic infection which is endemic in 21 countries with 10 million cases worldwide and 12,000 annual deaths. Around 70 million people in the Americas are at risk of contracting this disease, and less than 1% of infected people are treated due to low disease awareness and limited access to treatment. The current treatment for Chagas disease consists of benznidazole and nifurtimox under the World Health Organization (WHO) authorization protocol. The current treatment has limitations in terms of efficacy against the chronic phase of infection and side effects associated with prolonged therapy. This review provides an update on nifurtimox progress over the years and its recent approval by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of Chagas disease in pediatric patients under 18 years of age.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 4 vom: 14. Apr., Seite 251-263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thakare, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
American trypanosomiasis |
|---|
| Anmerkungen: |
Date Completed 15.04.2021 Date Revised 15.04.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.4.3251712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324065183 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324065183 | ||
| 003 | DE-627 | ||
| 005 | 20231225185526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.4.3251712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324065183 | ||
| 035 | |a (NLM)33851689 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thakare, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update on nifurtimox for treatment of Chagas disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2021 | ||
| 500 | |a Date Revised 15.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a Chagas disease is a vector-borne neglected tropical disease caused by Trypanosoma cruzi. It is a systemic and chronic parasitic infection which is endemic in 21 countries with 10 million cases worldwide and 12,000 annual deaths. Around 70 million people in the Americas are at risk of contracting this disease, and less than 1% of infected people are treated due to low disease awareness and limited access to treatment. The current treatment for Chagas disease consists of benznidazole and nifurtimox under the World Health Organization (WHO) authorization protocol. The current treatment has limitations in terms of efficacy against the chronic phase of infection and side effects associated with prolonged therapy. This review provides an update on nifurtimox progress over the years and its recent approval by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of Chagas disease in pediatric patients under 18 years of age | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a American trypanosomiasis | |
| 650 | 4 | |a Anti-infective therapy | |
| 650 | 4 | |a Antiparasitics | |
| 650 | 4 | |a Chagas disease | |
| 650 | 4 | |a Nifurtimox | |
| 650 | 4 | |a Treatment of protozoal diseases | |
| 650 | 7 | |a Trypanocidal Agents |2 NLM | |
| 650 | 7 | |a Nifurtimox |2 NLM | |
| 650 | 7 | |a M84I3K7C2O |2 NLM | |
| 700 | 1 | |a Dasgupta, A |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 4 vom: 14. Apr., Seite 251-263 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:4 |g day:14 |g month:04 |g pages:251-263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.4.3251712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 4 |b 14 |c 04 |h 251-263 | ||